Caribou Biosciences (CRBU) Share-based Compensation (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Share-based Compensation of $2.4 million for Q1 2026, down 39.28% year-over-year from $3.9 million in Q1 2025, and down 13.92% quarter-over-quarter from $2.7 million in Q4 2025.
Caribou Biosciences (CRBU) Share-based Compensation (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Share-based Compensation for 7 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 39.28% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $11.2 million (down 32.8% YoY), while the FY2025 annual figure was $12.7 million, down 24.1% from the prior year.
- Share-based Compensation fell to $2.4 million in Q1 2026 per CRBU's latest filing, from $2.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $31.5 million in Q2 2022 and bottomed at -$14.5 million in Q4 2022.
- Historically, Share-based Compensation has averaged $6.4 million across 5 years, with a median of $3.6 million in 2023.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 7552.77% — and 2023, when it slumped 88.62%.
- Caribou Biosciences' Share-based Compensation stood at -$14.5 million in 2022, then surged by 124.47% to $3.6 million in 2023, then grew by 9.98% to $3.9 million in 2024, then decreased by 29.99% to $2.7 million in 2025, then slipped by 13.92% to $2.4 million in 2026.
- Business Quant data shows CRBU's Share-based Compensation at $2.4 million in Q1 2026, $2.7 million in Q4 2025, and $2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Caribou Biosciences | 163.09 Mn | 50.78 Mn | - | 2.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.48 Mn |
| Jun 30, 2026 | 2.48 Mn |
| Mar 31, 2026 | 2.36 Mn |
| Mar 31, 2026 | 2.36 Mn |
| Dec 31, 2025 | 2.74 Mn |
| Dec 31, 2025 | 2.74 Mn |
| Sep 30, 2025 | 2.93 Mn |
| Sep 30, 2025 | 2.93 Mn |
| Jun 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 3.13 Mn |
| Mar 31, 2025 | 3.88 Mn |
| Mar 31, 2025 | 3.88 Mn |
| Dec 31, 2024 | 3.91 Mn |
| Dec 31, 2024 | 3.91 Mn |
| Sep 30, 2024 | 4.07 Mn |
| Sep 30, 2024 | 4.07 Mn |
| Jun 30, 2024 | 4.74 Mn |
| Jun 30, 2024 | 4.74 Mn |
| Mar 31, 2024 | 3.99 Mn |
| Mar 31, 2024 | 3.99 Mn |